Methylphenidate and the juvenile brain: Enhancement of attention at the expense of cortical plasticity?

Medical Hypotheses

Volumn 81, Issue 6, 2013, Pages 988-994

  Urban, Kimberly R ^a   Gao, Wen Jun ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPHENIDATE; NEUROTRANSMITTER;

ARTICLE; ATTENTION; ATTENTION DEFICIT DISORDER; BRAIN; BRAIN FUNCTION; EXECUTIVE FUNCTION; FRONTAL LOBE; HUMAN; LONG TERM POTENTIATION; MEDICAL LITERATURE; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NONHUMAN; PREFRONTAL CORTEX; PYRAMIDAL NERVE CELL; THINKING; WORKING MEMORY;

RATTUS; RODENTIA;

ADOLESCENT; AGE FACTORS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; HUMANS; METHYLPHENIDATE; MODELS, BIOLOGICAL; NEURONAL PLASTICITY; PREFRONTAL CORTEX; RATS;

EID: 84888428629     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.09.009     Document Type: Article

References (75)

1. Swanson J., Baler R.D., Volkow N.D. Understanding the effects of stimulant medications on cognition in individuals with attention-deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology 2011, 36(1):207-226.
2. Nair J., et al. Clinical review: evidence-based diagnosis and treatment of ADHD in children. Missouri Med 2006, 103(6):617-621.
3. Getahun D. Recent trends in childhood attention-deficit/hyperactivity disorder. JAMA Pediatr 2013, 1-7.
4. Heal D.J., Cheetham S.C., Smith S.L. The neuropharmacology of ADHD drugs in vivo: insights on efficacy and safety. Neuropharmacology 2009, 57(7-8):608-618.
5. Hazell P. Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder. Australas Psychiatry 2010, 18(6):556-559.
6. Urban K.R., Gao W.J. Evolution of the study of methylphenidate and its actions on the adult versus juvenile brain. J Atten Disord 2012, 24:24.
7. Barkley R.A., et al. Young adult follow-up of hyperactive children: antisocial activities and drug use. J Child Psychol Psychiatry 2004, 45(2):195-211.
8. Arnsten A.F. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 2006, 67(Suppl. 8):7-12.
9. Arnsten A.F., Li B.M. Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions. Biol Psychiatry 2005, 57(11):1377-1384.
10. Goldman-Rakic P.S. Cellular basis of working memory. Neuron 1995, 14(3):477-485.
11. Dalley J.W., Cardinal R.N., Robbins T.W. Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev 2004, 28(7):771-784.
12. Robbins T.W., Arnsten A.F. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci 2009, 32:267-287.
13. Challman T.D., Lipsky J.J. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000, 75(7):711-721.
14. Berridge C.W., Devilbiss D.M. Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Biol Psychiatry 2011, 69(12):e101-e111.
15. Yano M., Steiner H. Methylphenidate and cocaine: the same effects on gene regulation?. Trends Pharmacol Sci 2007, 28(11):588-596.
16. Kuczenski R., Segal D.S. Stimulant actions in rodents: implications for attention-deficit/hyperactivity disorder treatment and potential substance abuse. Biol Psychiatry 2005, 57(11):1391-1396.
17. Arnsten A.F., Scahill L., Findling R.L. Alpha2-adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol 2007, 17(4):393-406.
18. Berridge C.W., et al. Differential sensitivity to psychostimulants across prefrontal cognitive tasks: differential involvement of noradrenergic alpha -1 and alpha-2 receptors. Biol Psychiatry 2012, 71(5):467-473.
19. Arnsten A.F., Dudley A.G. Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 2005, 1(1):2.
20. Clatworthy P.L., et al. Dopamine release in dissociable striatal subregions predicts the different effects of oral methylphenidate on reversal learning and spatial working memory. J Neurosci 2009, 29(15):4690-4696.
21. Gamo N.J., Wang M., Arnsten A.F. Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors. J Am Acad Child Adolesc Psychiatry 2010, 49(10):1011-1023.
22. Spencer R.C., Klein R.M., Berridge C.W. Psychostimulants act within the prefrontal cortex to improve cognitive function. Biol Psychiatry 2012, 72(3):221-227.
23. Rapoport J.L., Buchsbaum M., Zahn T., Weingartner H., Ludlow C., Mikkelsen E. Dextroamphetamine: cognitive and behavioral effects in normal prepubertal boys. Science 1978, 199:560-563.
24. Rapoport J.L., Buchsbaum M., Zahn T., Weingartner H., Ludlow C., Mikkelsen E. Dextroamphetamine- its cognitive and behavioral effects in normal and hyperactive boys and normal men. Arch Gen Psychiatry 1980, 37:933-943.
25. Mehta M.A., Sahakian B.J., Mavaddat N., Pickard J.D., Robbins T.W. Comparative psychopharmacology of methylpyhenidate and related drugs in human volunteers, patients with ADHD, and experimental animals. Stimulant drugs and ADHD: basic and clinical neuroscience 2001, 303-331. Oxford University Press, New York.
26. Vaidya C.J., et al. Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad Sci USA 1998, 95(24):14494-14499.
27. Kuczenski R., Segal D.S. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci 2002, 22(16):7264-7271.
28. Volkow N.D., et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998, 155(10):1325-1331.
29. Volkow N.D., et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 2001, 21(2):RC121.
30. Volkow N.D., et al. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord 2002, 6(Suppl. 1):S31-S43.
31. Agay N., et al. Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults. Psychopharmacology (Berlin) 2010, 210(4):511-519.
32. Askenasy E.P., Taber K.H., Yang P.B., Dafny N. Methylphenidate (Ritalin): behavioral studies in the rat. Int J Neurosci 2007, 117:757-794.
33. Dow-Edwards D.L., Weedon J.C., Hellmann E. Methylphenidate improves performance on the radial arm maze in periadolescent rats. Neurotoxicol Teratol 2008, 30(5):419-427.
34. Linssen A.M., et al. Methylphenidate produces selective enhancement of declarative memory consolidation in healthy volunteers. Psychopharmacology (Berl) 2011.
35. Berridge C.W., et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006, 60(10):1111-1120.
36. Kuczenski R., Segal D.S. Locomotor effects of acute and repeated threshold doses of amphetamine and methylphenidate: relative roles of dopamine and norepinephrine. J Pharmacol Exp Ther 2001, 296(3):876-883.
37. Gray J.D., et al. Methylphenidate administration to juvenile rats alters brain areas involved in cognition, motivated behaviors, appetite, and stress. J Neurosci 2007, 27(27):7196-7207.
38. Berridge C.W., Devilbiss D.M., Andrzejewski M.E., Arnsten A.F., Kelley A.E., Schmeichel B., et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006, 60(10):1111-1120.
39. Gaytan O., et al. Sensitization to locomotor effects of methylphenidate in the rat. Life Sci 1997, 61(8):PL101-PL107.
40. Gaytan O., et al. Dose response characteristics of methylphenidate on different indices of rats' locomotor activity at the beginning of the dark cycle. Brain Res 1996, 727(1-2):13-21.
41. Levy F. Dopamine vs noradrenaline: inverted-U effects and ADHD theories. Aust N Z J Psychiatry 2009, 43(2):101-108.
42. Vijayraghavan S., et al. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci 2007, 10(3):376-384.
43. Devilbiss D.M., Waterhouse B.D. The effects of tonic locus ceruleus output on sensory-evoked responses of ventral posterior medial thalamic and barrel field cortical neurons in the awake rat. J Neurosci 2004, 24(48):10773-10785.
44. Arnsten A.F.T. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci 2009, 10(6):410-422.
45. Franke A.G., et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011, 44(2):60-66.
46. Goodman R. Cognitive enhancement, cheating, and accomplishment. Kennedy Inst Ethics J 2010, 20(2):145-160.
47. Andersen S.L., Teicher M.H. Stress, sensitive periods and maturational events in adolescent depression. Trends Neurosci 2008, 31(4):183-191.
48. Blakemore S.J. The social brain in adolescence. Nat Rev Neurosci 2008, 9(4):267-277.
49. Kolb B., et al. Experience and the developing prefrontal cortex. Proc Nat Acad Sci 2012, 109(Suppl. 2):17186-17193.
50. Casey B.J., Jones R.M., Hare T.A. The adolescent brain. Ann N Y Acad Sci 2008, 1124:111-1126.
51. Gao W.-J., et al. The unique properties of the prefrontal cortex and mental illness. When things go wrong - Diseases and disorders of the human brain 2012, 3-26. InTech.
52. Kanitz E., et al. Age-related changes in corticosteroid receptor expression and monoamine neurotransmitter concentrations in various brain regions of postnatal pigs. J Neurosci Res 2011, 89(7):1134-1141.
53. Algahim M.F., et al. Repetitive ritalin treatment modulates the diurnal activity pattern of young SD male rats. Cent Nerv Syst Agents Med Chem 2010, 10(3):247-257.
54. Lee M.J., et al. Does repetitive Ritalin injection produce long-term effects on SD female adolescent rats?. Neuropharmacology 2009, 57(3):201-207.
55. Andersen S.L., et al. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat Neurosci 2002, 5(1):13-14.
56. Torres-Reveron A., Weedon J., Dow-Edwards D.L. Methylphenidate response in prenatal cocaine-exposed rats: a behavioral and brain functional study. Brain Res 2010, 1337:74-84.
57. Jernigan T.L., et al. Maturation of human cerebrum observed in vivo during adolescence. Brain 1991, 114(Pt 5):2037-2049.
58. Kuboshima-Amemori S., Sawaguchi T. Plasticity of the primate prefrontal cortex. Neuroscientist 2007, 13(3):229-240.
59. Paoletti P., Bellone C., Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 2013, 14(6):383-400.
60. Yashiro K., Philpot B.D. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology 2008, 55(7):1081-1094.
61. Cull-Candy S., Brickley S., Farrant M. NMDA receptor subunits: diversity, development and disease. Curr Opin Neurobiol 2001, 11(3):327-335.
62. Wang H., et al. A specialized NMDA receptor function in layer 5 recurrent microcircuitry of the adult rat prefrontal cortex. Proc Natl Acad Sci USA 2008, 105(43):16791-16796.
63. Wang M., et al. NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex. Neuron 2013, 77(4):736-749.
64. Urban K.R., Waterhouse B.D., Gao W.J. Distinct age-dependent effects of methylphenidate on developing and adult prefrontal neurons. Biol Psychiatry 2012, 72(10):880-888.
65. Devilbiss D.M., Berridge C.W. Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness. Biol Psychiatry 2008, 64(7):626-635.
66. Waterhouse, B.D., K.L. Agster, and B.D. Calrk, The effects of methylphenidate on sensory signal processing in the rodent lateral geniculate nucleus Society for Neuroscience 2008. Abstract (Washington, DC,): p. Program No. 161.5.
67. Cepeda C., Levine M.S. Where do you think you are going? The NMDA-D1 receptor trap. Sci STKE 2006, 2006(333):pe20-pe24.
68. Kopp C., Longordo F., Luthi A. Experience-dependent changes in NMDA receptor composition at mature central synapses. Neuropharmacology 2007, 53(1):1-9.
69. Li Y.C., et al. Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci 2009, 29(49):15551-15563.
70. Mao L.M., et al. Stability of surface NMDA receptors controls synaptic and behavioral adaptations to amphetamine. Nat Neurosci 2009, 12(5):602-610.
71. Urban K.R., Li Y.C., Gao W.J. Treatment with a clinically-relevant dose of methylphenidate alters NMDA receptor composition and synaptic plasticity in the juvenile rat prefrontal cortex. Neurobiol Learn Mem 2012, 101:65-74.
72. Foster K.A., et al. Distinct roles of NR2A and NR2B cytoplasmic tails in long-term potentiation. J Neurosci 2010, 30(7):2676-2685.
73. Massey P.V., Johnson B.E., Moult P.R., Auberson Y.P., Brown M.W., Molnar E., et al. Differential roles of NR2A and NR2B-containing NMDA receptors in cortical long-term potentiation and long-term depression. J Neurosci 2004, 24:7821-7828.
74. Xu Z., et al. Metaplastic regulation of long-term potentiation/long-term depression threshold by activity-dependent changes of NR2A/NR2B ratio. J Neurosci 2009, 29(27):8764-8773.
75. Ghanizadeh A. Psychometric analysis of the new ADHD DSM-V derived symptoms. BMC Psychiatry 2012, 12:21.